



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY
820 CHANDLER STREET
FORT DETRICK MD 21702-5014

19 August 2020

Advanced Technology International (ATI)
ATTN: (b) (6), Contracts Administrator
315 Sigma Drive
Summerville, SC 29486

Dear (b) (6):

SUBJECT: Project Approval Letter (PAL) for 20-09-COVID19-050 for “Rapid development of an (b) (4) of pandemic COVID-19”

REF: Request for Project Approval from ATI dated 31 July 2020 for 20-09-COVID19-050 under OTA W81XWH-15-9-0001

EGS#: MT20009.50

In support of the U.S. Army Medical Research and Development Command (USAMRDC), ATI, on behalf of the Medical Technology Enterprise Consortium (MTEC) issued RPP 20-09-COVID19 on 25 March 2020. Members of the MTEC submitted Enhanced White Papers in response to this RPP, in accordance with the terms of the RPP and the Proposal Preparation Guide (PPG). (b) (4)

Subsequently, the Government evaluated technical proposals in accordance with the stated evaluation criteria; (b) (4)

Based upon the evaluation of Centivax, Inc.’s proposal (20-09-COVID19-050) entitled, “Rapid development of an (b) (4) of pandemic COVID-19,” and ATI’s request for PAL (which includes the Statement of Work (SOW), inclusive of an acceptable milestone schedule), ATI is hereby authorized to issue a Research Project Award (RPA) to Centivax, Inc. for the subject initiative. This approval is contingent upon the provision of funding via a separate Other Transaction Agreement Task Order, W81XWH-20-9-0008. At no time shall the Government’s obligation exceed the funding provided for this RPA. The Sponsor Office Technical Representative (SOTR) for this RPA is (b) (6)

The period of performance of the Research Project Award is 8 months. Note, however, that the period of performance within the Other Transaction Agreement Task Order, W81XWH-20-9-0008, includes additional time to account for the final negotiations between ATI and (b) (4) to finalize negotiations for the RPA. This additional time is intended to align the end dates for the Task Order and RPA.

SUBJECT: PAL for 20-09-COVID19-050 for “Rapid development of an (b) (4) of pandemic COVID-19”

SPECIAL CONSIDERATIONS

External reviews and special considerations apply to this Research Project Award including use of animal subjects and use of human subjects. U.S. Army Medical Research and Development Command’s (USAMRDC) Office of Research Protections, Human Research Protections Office (HRPO) approval must be obtained prior to commencement of any work involving human use. Approval from the MRDC Animal Care and Use Review Office (ACURO) must be obtained prior to commencement of the tasks involving animal use.

PRE-AWARD COSTS

The Government has authorized pre-award costs for Research Project Award for Centivax’s proposal 20-09-COVID-19-050 starting 27 May 2020 in an amount not to exceed \$190,500.00. The Government agrees to pay allowable costs accrued in the performance of this Research Project Award starting 27 May 2020 through the end of the period of performance.

The total authorized value has been determined fair and reasonable and this proposal has been selected IAW the RPP evaluation criteria. The Agreements Officer documented the appropriate use of Section 815 prototype OTA authority. The total approved cost to the Government for this effort is Not-to-Exceed (NTE) \$1,206,824.00 as follows:

Government Project Funding	ATI Fixed Fee (Gov’t Funding)	Total Cost to the Government	Anticipated Non-Federal Contribution	Total Project Cost
\$1,206,824.00	\$0.00	\$1,206,824.00	\$0.00	\$1,206,824.00

Sincerely,

BARTLETT.C Digitally signed
HARLES.J.10 by
42185180 BARTLETT.CHARL
ES.J.1042185180

Charles J. Bartlett
Agreements Officer

Enclosed:
Statement of Work with Milestones